Skip to main content

Lumos Pharma, Inc.

LUMODelisted Dec 12, 2024
Industry
Pharmaceutical Preparations
SEC CIK
0001126234

Lumos Pharma, Inc. was delisted on Dec 12, 2024; its insiders filed their last Form 4 on Dec 13, 2024; 29 institutions reported holding it in 13F filings for Q3 2024, worth $8.08M in total; no superinvestor held it.

Holders of 5% or more of LUMO

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Lumos Pharma, Inc., largest stake first. The change is against the holder's previous filing.

No holder currently reports owning 5% or more of Lumos Pharma, Inc. on Schedule 13D or 13G.

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

21 Schedule 13D and 13G filings on Lumos Pharma, Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on LUMO
Filed (ET)FilerFormStakeChangeEvent dateFiling
Feb 13, 20254:16 PM ETPrivate Advisor Group, LLC13G/A0.00%–Below 5%Dec 31, 2024SEC
Feb 13, 20254:02 PM ETGoldman Sachs Group Incand 1 other13G/A0.00%0 shares–Below 5%Dec 31, 2024SEC
Nov 12, 2024Private Advisor Group, LLC13GOld format–New–SEC
Oct 25, 202410:43 AM ETWells Fargo & Company13G/A0.80%65.0K shares–Below 5%Sep 30, 2024SEC
Feb 9, 2024Goldman Sachs Group Inc13G/AOld format–––SEC
Feb 6, 2024Wells Fargo & Company13GOld format–New–SEC
Nov 29, 2023Blackstone Holdings II L.P.13D/AOld format–––SEC
Jun 20, 2023Farb Daniel Stuart13D/AOld format–––SEC
Jun 2, 2023Farb Daniel Stuart13D/AOld format–––SEC
May 25, 2023Farb Daniel Stuart13D/AOld format–––SEC
Feb 15, 2023Farb Daniel Stuart13DOld format–––SEC
Feb 7, 2023Goldman Sachs Group Inc13GOld format–New–SEC
Jan 24, 2023Farb Daniel Stuart13G/AOld format–––SEC
Feb 2, 2022Farb Daniel Stuart13G/AOld format–––SEC
Feb 1, 2022Farb Daniel Stuart13GOld format–New–SEC
Jan 5, 2022New Enterprise Associates 14, L.P.13D/AOld format–––SEC
Aug 30, 2021SHV Management Services II, LP13DOld format–New–SEC
May 26, 2021Flynn James E13G/AOld format–––SEC
Feb 12, 2021Flynn James E13G/AOld format–––SEC
Feb 12, 2021Lion Point Capital, LP13G/AOld format–––SEC
Feb 11, 2021Renaissance Technologies LLC13G/AOld format–––SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell Lumos Pharma, Inc. shares.

No Form 144 notices for Lumos Pharma, Inc. are on file.